CAP Profiles

Bio

Bio

Dr Basina is a clinical endocrinologist and clinical researcher with a focus on diabetes management, thyroid, and adrenal conditions. Her primary interests are in Type 1 Diabetes, Diabetes technology, and Diabetes in pregnancy. Dr Basina is Board certified in Endocrinology and Internal Medicine.
She received numerous teaching awards and Stanford Hospital award for excellence in patient care.
She is an active member of medical advisory boards for several community diabetes organizations. Dr Basina is a medical director of inpatient diabetes program at Stanford and a chair of diabetes task force.

Clinical Focus

  • Endocrinology
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Thyroid Diseases
  • Diabetes and Metabolism
  • adrenal disorders

Academic Appointments

Administrative Appointments

  • Medical Director of Inpatient Diabetes, Stanford Hospital and Clinics (2012 - Present)

Honors & Awards

  • Top Recommended Doctor, Bay Area Consumer Report Magazine (2007)
  • House staff Award for Demonstrating Excellence in Clinical Teaching, Kaiser Permanente Internal Medicine Residency Program (2004)
  • Alwin C. Rambar-James B. D. Mark Award for Excellence in patient care, Stanford University (2014)
  • Stanford University Division of Endocrinology Fellows Teaching Award, Stanford University (2009, 2010, 2012, 2013, 2014, 2015)

Boards, Advisory Committees, Professional Organizations

  • Member, American Diabetes Association (2001 - Present)
  • Member, Endocrine Society (2001 - Present)
  • Chair Diabetes Task Force, Stanford University (2009 - Present)
  • Advisory Board Member, CarbDM Seize Diabetes (2012 - Present)
  • Advisory Board Member, Cardiac Therapy Foundation (2012 - Present)

Professional Education

  • Fellowship:Stanford University School of Medicine Registrar (2003) CA
  • Medical Education:Second Moscow Medical University (1987) Russia
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2001)
  • Board Certification, American Board of Internal Medicine, Endocrinology, Diabetes and Metabolism (2013)
  • Board Certification: Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine (2003)
  • Residency:UCLA/West Los Angeles VAMC (2001) CA
  • Internship:UCLA/West Los Angeles VAMC (1999) CA
  • Board Certification, Board of Internal Medicine, Internal Medicine (2001)
  • Board Certification, Board of Internal Medicine, Endocrinology and Diabetes (2003)
  • Fellowship, Stanford University, Endocrinology (2003)
  • Residency, UCLA/West LA VA, Internal Medicine (2001)
  • Internship, UCLA/West LA VA, Medicine (1999)
  • MD, Moscow Medical School, Russia, Medicine (1987)

Contact

  • Endocrine Clinic within Ambulatory Care Clinic 300 Pasteur Dr Rm A175 Stanford, CA 94305
    • Tel: (650) 721-1300
    Fax: (650) 725-8418

Research & Scholarship

Current Research and Scholarly Interests

Type I and type II diabetes, insulin pump therapy, glucose sensor technology, insulin resistance, PCOS, thyroid disorders

Clinical Trials

  • Rosiglitazone-Induced Weight Gain Not Recruiting

    Given the high prevalence of type 2 diabetes and the 2- to 4-fold increased risk of fatal and non-fatal coronary heart disease events in these patients, long-term glycemic control is of great importance. TZDs improves glycemic control in patients with type 2 DM as well as enhances their insulin-mediated glucose disposal. However, the improvement of glycemic control seen with TZDs may be blunted in the long run by weight gain. Previous data on weight gain during TZD therapy in patients with type 2 DM is very sparse. It is generally assumed that an increase in adipocyte differentiation is the cause of weight gain in association with TZD treatment which may limit their use. Increased body weight assumed to compromise the positive effects of treatment. There is also a theoretical concern that, with the development of new adipocytes, future weight loss may be difficult. However, if weight gain is primarily due to failure to adjust caloric intake in proportion to the decrease in urinary glucose loss, it is totally preventable. It has been previously shown that improvement of glycemia favored weight gain by decreasing the energy loss in the urine as glucose. Severity of weight gain appears to be proportional to the level of glycemic control achieved. The overall goal of the proposed research is to provide the experimental evidence for the later alternative by showing that the modest weight gain that takes place in association with effective rosiglitazone treatment of hyperglycemic patients with type 2 DM is primarily due to its therapeutic efficacy. More specifically, by decreasing the caloric intake in proportion to a decrease in urinary glucose loss associated with improved glycemic control, we will be able to prevent significant weight gain following Rosiglitazone treatment. In order to provide an optimal dietary modification that can be universally applied to TZD-treated patients in clinical practice, we will have a group with a fixed amount of caloric restriction per day. It will be the first randomized controlled trial of a potential strategy for prevention of weight gain associated with thiazolidinediones.

    Stanford is currently not accepting patients for this trial. For more information, please contact Marina Basina, MD, 510-752-6332.

    View full details

Teaching

2017-18 Courses

Publications

All Publications

  • Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocrine practice Basina, M., Liu, H., Hoffman, A. R., Feldman, D. 2012; 18 (5): e114-20

    Abstract

    We describe a girl with Cushing disease for whom surgery and radiation treatments failed and the subsequent clinical course with mifepristone therapy.We present the patient's clinical, biochemical, and imaging findings.A 16-year-old girl presented with classic Cushing disease. After transsphenoidal surgery, Cyberknife radiosurgery, ketoconazole, and metyrapone did not control her disease, and she was prescribed mifepristone, which was titrated to a maximal dosage of 1200 mg daily with subsequent symptom improvement. Mifepristone (RU486) is a high-affinity, nonselective antagonist of the glucocorticoid receptor. There is limited literature on its use as an off-label medication to treat refractory Cushing disease. Over her 8-year treatment with mifepristone, her therapy was complicated by hypertension and hypokalemia requiring spironolactone and potassium chloride. She received a 2-month drug holiday every 4 to 6 months to allow for withdrawal menstrual bleeding with medroxyprogesterone acetate. Urinary cortisol, serum cortisol, and corticotropin levels remained elevated during mifepristone drug holidays. While on mifepristone, her signs and symptoms of Cushing disease resolved. Repeated magnetic resonance imaging demonstrated stable appearance of the residual pituitary mass. Bilateral adrenalectomy was performed, and mifepristone was discontinued after 95 months of medical therapy.We describe the longest duration of mifepristone therapy thus reported for the treatment of refractory Cushing disease. Mifepristone effectively controlled all signs and symptoms of hypercortisolism. Menstruating women who take the drug on a long-term basis should receive periodic drug holidays to allow for menses. The lack of reliable serum biomarkers to monitor the success of mifepristone therapy requires careful clinical judgment and may make its use difficult in Cushing disease.

    View details for DOI 10.4158/EP11391.CR

    View details for PubMedID 22441000

  • Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes - Comparison of moderate fat versus carbohydrate reductions DIABETES CARE McLaughlin, T., Carter, S., Lamendola, C., Abbasi, F., Schaaf, P., Basina, M., Reaven, G. 2007; 30 (7): 1877-1879

    View details for DOI 10.2337/dc07-0301

    View details for Web of Science ID 000247768400036

    View details for PubMedID 17475941

  • Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults AMERICAN JOURNAL OF CLINICAL NUTRITION McLaughlin, T., Carter, S., Lamendola, C., Abbasi, F., Yee, G., Schaaf, P., Basina, M., Reaven, G. 2006; 84 (4): 813-821

    Abstract

    Obese, insulin-resistant persons are at risk of cardiovascular disease. How best to achieve both weight loss and clinical benefit in these persons is controversial, and recent reports questioned the superiority of low-fat diets.We aimed to ascertain the effects of moderate variations in the carbohydrate and fat content of calorie-restricted diets on weight loss and cardiovascular disease risk in obese, insulin-resistant persons.Fifty-seven randomly assigned, insulin-resistant, obese persons completed a 16-wk calorie-restricted diet with 15% of energy as protein and either 60% and 25% or 40% and 45% of energy as carbohydrate and fat, respectively. Baseline and postweight-loss insulin resistance; daylong glucose, insulin, and triacylglycerol concentrations; fasting lipid and lipoprotein concentrations; and markers of endothelial function were quantified.Weight loss with 60% or 40% of energy as carbohydrate (5.7 +/- 0.7 or 6.9 +/- 0.7 kg, respectively) did not differ significantly, and improvement in insulin sensitivity correlated with the amount of weight lost (r = 0.50, P < 0.001). Subjects following the diet with 40% of energy as carbohydrate had greater reductions in daylong insulin and triacylglycerol (P < 0.05) and fasting triacylglycerol (0.53 mmol/L; P = 0.04) concentrations, greater increases in HDL-cholesterol concentrations (0.12 mmol/L; P < 0.01) and LDL particle size (1.82 s; P < 0.05), and a greater decrease in plasma E-selectin (5.6 ng/L; P = 0.02) than did subjects following the diet with 60% of energy as carbohydrate.In obese, insulin-resistant persons, a calorie-restricted diet, moderately lower in carbohydrate and higher in unsaturated fat, is as efficacious as the traditional low-fat diet in producing weight loss and may be more beneficial in reducing markers for cardiovascular disease risk.

    View details for Web of Science ID 000241140700019

    View details for PubMedID 17023708

  • Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome HUMAN REPRODUCTION Cataldo, N. A., Abbasi, F., McLaughlin, T. L., Basina, M., Fechner, P. Y., Giudice, L. C., Reaven, G. M. 2006; 21 (1): 109-120

    Abstract

    Insulin sensitizers have favourable metabolic and ovarian effects in polycystic ovary syndrome (PCOS). This study examined rosiglitazone, a thiazolidinedione, in PCOS.In a prospective, open-label study, the effects of rosiglitazone on metabolism and ovarian function were examined in 42 non-diabetic women with PCOS classified according to the National Institute of Child Health and Human Development criteria and insulin resistance (IR) by steady-state plasma glucose (SSPG) > or =10 mmol/l on octreotide-modified insulin suppression testing. Participants were randomized to rosiglitazone 2, 4 or 8 mg daily for 12 weeks. Endpoints included ovulation and menstrual pattern; serum testosterone, sex hormone-binding globulin (SHBG), and LH; and changes in IR and glucose-insulin responses on 8 h mixed-meal profile.After rosiglitazone 8 mg daily for 12 weeks, SSPG declined and insulinaemia fell by 46%; lower doses gave lesser effects. Serum LH, total and free testosterone were unchanged; SHBG increased. With rosiglitazone, ovulation occurred in 23/42 women (55%), without significant dose dependence. Both before and during treatment, ovulators on rosiglitazone had lower circulating insulin and free testosterone and higher SHBG than non-ovulators. Testosterone declined only in a subgroup of ovulators with early vaginal bleeding after starting rosiglitazone.Rosiglitazone in insulin-resistant PCOS promoted ovulation and dose-dependently decreased IR and insulinaemia; ovulators had lower circulating insulin and testosterone.

    View details for DOI 10.1093/humrep/dei289

    View details for Web of Science ID 000233846700014

    View details for PubMedID 16155076

  • Effectiveness of Diabetes Management: is Improvement Feasible? American Journal of Medicine Marina Basina, Frederick B Kraemer 2002; 112 (8)
  • Utilization of Thyrogen. Thyroid Weisler, S., Basina, M, Hershman JM 2001; 11 (11)